EUVIMEDEUVIMED entdecken
Open Access

Reduced Odds of Mpox-Associated Hospitalization Among Persons Who Received JYNNEOS Vaccine — California, May 2022–May 2023

Samuel Schildhauer, Kayla Saadeh, Josh Vance, Joshua Quint, Tarek Salih, Timothy Lo, Awa Keinde, Edwin Chojolan, Esther Gotlieb, Marisa Ramos, Eric Chapman, Philip Peters und 5 weitere

MMWR. Morbidity and Mortality Weekly Report · 08.09.2023 · 72 (36) · 992-996

DOI: 10.15585/mmwr.mm7236a4 ↗

Kurz gefasst

Fachartikel in der Zeitschrift MMWR. Morbidity and Mortality Weekly Report, online erschienen am 08.09.2023. Verfasst von Samuel Schildhauer und 16 weiteren Autor:innen. Hauptthemen laut MEDLINE: HIV Infections, Mpox, Monkeypox. Die Arbeit wurde bisher 26-mal zitiert (Crossref) und nennt 10 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The effectiveness of 1 dose of JYNNEOS vaccine (modified vaccinia Ankara vaccine, Bavarian Nordic) against hospitalization for mpox (caused by Monkeypox virus), has been demonstrated; however, the impact of 2 doses on hospitalization risk, especially among persons infected with HIV, who are at higher risk for severe disease, is an important factor in evaluating vaccine effectiveness against mpox disease severity and Monkeypox virus infection. Surveillance data collected by the California Department of Public Health were used to evaluate whether receipt of 2 doses of JYNNEOS vaccine reduced the odds of hospitalization among persons with mpox. The odds of hospitalization among persons with mpox who had received 1 or 2 JYNNEOS doses were 0.27 (95% CI = 0.08-0.65) and 0.20 (95% CI = 0.01-0.90), respectively, compared with unvaccinated mpox patients. In mpox patients with HIV infection, the odds of hospitalization among those who had received 1 JYNNEOS vaccine dose was 0.28 (95% CI = 0.05-0.91) times that of those who were unvaccinated. No mpox-associated hospitalizations were identified among persons infected with HIV who had received 2 JYNNEOS vaccine doses. To optimize durable immunity, all eligible persons at risk for mpox, especially those infected with HIV, should complete the 2-dose JYNNEOS series.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HIV InfectionsMpox, MonkeypoxHumansCaliforniaHospitalizationMonkeypox virusVaccines, AttenuatedSmallpox Vaccine

Substanzen

Vaccines, Attenuatedsmallpox and monkeypox vaccine modified vaccinia ankara-bavarian nordicSmallpox Vaccine

Zitieren

APA

Schildhauer, S., Saadeh, K., Vance, J., Quint, J., Salih, T., Lo, T., Keinde, A., Chojolan, E., Gotlieb, E., Ramos, M., Chapman, E., Peters, P., Watson, J., Johnson, K. A., Tang, E. C., Jacobson, K., & Snyder, R. E. (2023). Reduced Odds of Mpox-Associated Hospitalization Among Persons Who Received JYNNEOS Vaccine — California, May 2022–May 2023. MMWR. Morbidity and Mortality Weekly Report, 72(36), 992-996. https://doi.org/10.15585/mmwr.mm7236a4

Vancouver

Schildhauer S, Saadeh K, Vance J, Quint J, Salih T, Lo T, et al. Reduced Odds of Mpox-Associated Hospitalization Among Persons Who Received JYNNEOS Vaccine — California, May 2022–May 2023. MMWR. Morbidity and Mortality Weekly Report. 2023;72(36):992-996. doi:10.15585/mmwr.mm7236a4

BibTeX
@article{Schildhauer2023,
  author = {Schildhauer, Samuel and Saadeh, Kayla and Vance, Josh and Quint, Joshua and Salih, Tarek and Lo, Timothy and Keinde, Awa and Chojolan, Edwin and Gotlieb, Esther and Ramos, Marisa and Chapman, Eric and Peters, Philip and Watson, Jessica and Johnson, Kelly A and Tang, Eric C and Jacobson, Kathleen and Snyder, Robert E},
  title = {Reduced Odds of Mpox-Associated Hospitalization Among Persons Who Received JYNNEOS Vaccine — California, May 2022–May 2023},
  journal = {MMWR. Morbidity and Mortality Weekly Report},
  year = {2023},
  volume = {72},
  number = {36},
  pages = {992--996},
  doi = {10.15585/mmwr.mm7236a4}
}
Kostenlos starten →